The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia - PubMed (original) (raw)
. 2000 Jan 15;95(2):627-32.
Affiliations
- PMID: 10627472
Free article
The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia
D Jones et al. Blood. 2000.
Free article
Abstract
Chemotaxis in leukocytes is mediated through binding of soluble chemokines to transmembrane G-protein coupled receptors. The chemokine receptor CXCR3 has been previously shown to be widely expressed on activated T cells and to mediate T-cell chemotaxis on binding to various ligands, including Mig, IP-10, and ITAC. By using immunohistochemical and flow cytometric analysis, we report that CXCR3 is also expressed on a subset of peripheral blood B cells and in distinct subtypes of B-cell lymphoma. CXCR3 immunohistochemical or flow cytometric expression was seen in 37 of 39 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (diffusely positive in 33 cases), whereas mantle cell lymphoma (30 cases), follicular lymphoma (27 cases), and small noncleaved cell lymphoma (8 cases) were negative in all but 2 cases. Strong CXCR3 expression was also seen in splenic marginal zone lymphoma (14 of 14 cases) and in the monocytoid and plasmacytic cells in extranodal marginal zone lymphoma (15 of 16 cases). This differential expression of CXCR3 in B-cell tumors contrasts with that of another B-cell-associated chemokine receptor, BLR1/CXCR5, which we show here is expressed on all types of B-cell lymphoma tested. We also report that the CXCR3 ligand, Mig, is coexpressed on tumor cells in many cases of CLL/SLL (10 of 13 cases examined) with Mig expression less frequently seen in other B-cell lymphoma subtypes. Coexpression of CXCR3 and its ligand, Mig, may be an important functional interaction in B-CLL, as well as a useful diagnostic marker for the differential diagnosis of small cell lymphomas. (Blood. 2000;95:627-632)
Similar articles
- Expression of chemokine receptor CXCR3 and its ligand, mig, in gastric and thyroid marginal zone lymphomas. Possible migration and autocrine mechanism.
Ohshima K, Suefuji H, Karube K, Hamasaki M, Hatano B, Tutiya T, Yamaguchi T, Suzuki K, Suzumiya J, Kikuchi M. Ohshima K, et al. Leuk Lymphoma. 2003 Feb;44(2):329-36. doi: 10.1080/1042819031000060546. Leuk Lymphoma. 2003. PMID: 12688353 - The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis.
Trentin L, Agostini C, Facco M, Piazza F, Perin A, Siviero M, Gurrieri C, Galvan S, Adami F, Zambello R, Semenzato G. Trentin L, et al. J Clin Invest. 1999 Jul;104(1):115-21. doi: 10.1172/JCI7335. J Clin Invest. 1999. PMID: 10393705 Free PMC article. - CXCR3-positive B cells found at elevated frequency in the peripheral blood of patients with MALT lymphoma are attracted by MIG and belong to the lymphoma clone.
Suefuji H, Ohshima K, Karube K, Kawano R, Nabeshima K, Suzumiya J, Hayabuchi N, Kikuchi M. Suefuji H, et al. Int J Cancer. 2005 May 10;114(6):896-901. doi: 10.1002/ijc.20823. Int J Cancer. 2005. PMID: 15645433 - Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma.
Yoshino T, Tanaka T, Sato Y. Yoshino T, et al. J Clin Exp Hematop. 2020 Dec 15;60(4):124-129. doi: 10.3960/jslrt.19041. Epub 2020 Apr 3. J Clin Exp Hematop. 2020. PMID: 32249238 Free PMC article. Review. - The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies.
Burger JA, Gribben JG. Burger JA, et al. Semin Cancer Biol. 2014 Feb;24:71-81. doi: 10.1016/j.semcancer.2013.08.011. Epub 2013 Sep 7. Semin Cancer Biol. 2014. PMID: 24018164 Review.
Cited by
- Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity.
Bende RJ, Aarts WM, Riedl RG, de Jong D, Pals ST, van Noesel CJ. Bende RJ, et al. J Exp Med. 2005 Apr 18;201(8):1229-41. doi: 10.1084/jem.20050068. J Exp Med. 2005. PMID: 15837810 Free PMC article. - Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma.
Saber MM. Saber MM. J Immunol Res. 2023 Jan 23;2023:4556586. doi: 10.1155/2023/4556586. eCollection 2023. J Immunol Res. 2023. PMID: 36726488 Free PMC article. - The chemokine receptors CXCR4 and CXCR3 in cancer.
Fulton AM. Fulton AM. Curr Oncol Rep. 2009 Mar;11(2):125-31. doi: 10.1007/s11912-009-0019-1. Curr Oncol Rep. 2009. PMID: 19216844 Review. - B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21.
Hagn M, Blackwell SE, Beyer T, Ebel V, Fabricius D, Lindner S, Stilgenbauer S, Simmet T, Tam C, Neeson P, Trapani JA, Schrezenmeier H, Weiner GJ, Jahrsdörfer B. Hagn M, et al. Int Immunol. 2014 Jul;26(7):383-95. doi: 10.1093/intimm/dxu001. Epub 2014 Feb 4. Int Immunol. 2014. PMID: 24497611 Free PMC article. - Investigation of proliferation and migration of tongue squamous cell carcinoma promoted by three chemokines, MIP-3α, MIP-1β, and IP-10.
Chu H, Jia B, Qiu X, Pan J, Sun X, Wang Z, Zhao J. Chu H, et al. Onco Targets Ther. 2017 Aug 29;10:4193-4203. doi: 10.2147/OTT.S132855. eCollection 2017. Onco Targets Ther. 2017. PMID: 28919775 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials